Capital Advisors Ltd’s Century Therapeutics IPSC Stock Holding History

Capital Advisors Ltd’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-34	Closed	–	–	1409
2022 Q3	$0	Buy	+34	New	+$358	﹤0.01%	1355

Other funds holding IPSC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Capital Advisors Ltd's IPSC Position: Q4 2022 in Review

Capital Advisors Ltd sold out of Century Therapeutics (IPSC) in Q4 2022, closing a stake of 34 shares.

Capital Advisors Ltd first reported a position in IPSC in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 65 funds tracked by Wall St. Rank hold IPSC as of Q4 2022.

Capital Advisors Ltd reported no remaining Century Therapeutics position as of Q4 2022 after selling out during the quarter.
Capital Advisors Ltd sold 34 Century Therapeutics shares in Q4 2022.
Capital Advisors Ltd first reported a position in Century Therapeutics in Q3 2022 and held it in 1 quarter.
Capital Advisors Ltd's Century Therapeutics position peaked at $0 in Q3 2022.
65 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2022.

Based on Capital Advisors Ltd's 13F filing for Q4 2022, filed 7 Feb 2023.